68 related articles for article (PubMed ID: 19638019)
1. Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
Peinert S; Carney D; Prince HM; Januszewicz EH; Seymour JF
Br J Haematol; 2009 Sep; 146(6):685-6. PubMed ID: 19638019
[No Abstract] [Full Text] [Related]
2. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Zinzani PL; Stefoni V; Musuraca G; Tani M; Alinari L; Gabriele A; Marchi E; Pileri S; Baccarani M
Cancer; 2004 May; 100(10):2190-4. PubMed ID: 15139063
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
6. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
7. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
10. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
[TBL] [Abstract][Full Text] [Related]
11. Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
Rocco S; Improta S; Sagristani M; Quirino AA; Nitrato Izzo G; Russolillo S; Polistina MT; Mastrullo L
Haematologica; 2004 Jun; 89(6 Suppl):ECR19. PubMed ID: 15194555
[No Abstract] [Full Text] [Related]
12. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
13. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
14. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment.
Nakamura S; Matsumoto T; Suekane H; Nakamura S; Matsumoto H; Esaki M; Yao T; Iida M
Cancer; 2005 Aug; 104(3):532-40. PubMed ID: 15937928
[TBL] [Abstract][Full Text] [Related]
16. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
Oh SY; Ryoo BY; Kim WS; Kim K; Lee J; Kim HJ; Kwon JM; Lee HR; Ko YH; Oh SJ; Park KW; Kim HJ; Kwon HC; Nam E; Kim JH; Park YH; Lee SS; Kim HY; Park K
Ann Hematol; 2006 Nov; 85(11):781-6. PubMed ID: 16847665
[TBL] [Abstract][Full Text] [Related]
17. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe N; Tanimoto TE; Shimoda K; Hikiji W; Mitsugi K; Takase K; Henzan H; Numata A; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Haematologica; 2004 Jun; 89(6 Suppl):EIM14. PubMed ID: 15194556
[No Abstract] [Full Text] [Related]
18. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
19. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination.
Arcaini L; Burcheri S; Rossi A; Passamonti F; Paulli M; Boveri E; Brusamolino E; Orlandi E; Molteni A; Pulsoni A; Cox MC; Orsucci L; Fabbri A; Frezzato M; Voso MT; Zaja F; Montanari F; Pascutto C; Morra E; Cortelazzo S; Lazzarino M
Oncologist; 2006 Mar; 11(3):285-91. PubMed ID: 16549813
[TBL] [Abstract][Full Text] [Related]
20. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
